Literature DB >> 9289325

[The IBERPOC project: an epidemiological study of COPD in Spain. Scientific Committee of the IBERPOC study].

.   

Abstract

The aim of the IBERPOC study is to determine the prevalence of chronic obstructive pulmonary disease in Spain, to collect data on its management, the degree of variability in diagnosis, treatment and quality of life, and to estimate the mean annual direct health costs for these patients. IBERPOC is a multicentric transversal epidemiologic study that selects participants from populations corresponding to geographic and/or administrative areas using a probabilistic formula. Included are both males and females between 40 and 69 years of age who are residents in the study area and living outside institutions. This article describes the study design, sample selection criteria, the method and its application, and control systems used to prevent errors in patient selection and in pulmonary function testing. The schedule for data analysis is also included.

Entities:  

Mesh:

Year:  1997        PMID: 9289325

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  2 in total

1.  [Perceptions of patients and health professionals about the quality of care provided to chronic obstructive pulmonary disease patients].

Authors:  Elena Tambo-Lizalde; José Miguel Carrasco-Gimeno; Susana Mayoral-Blasco; María José Rabanaque-Hernández; José María Abad-Díez
Journal:  Aten Primaria       Date:  2015-05-19       Impact factor: 1.137

2.  Development and Preliminary Evaluation of the Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial.

Authors:  Begoña Jiménez-Reguera; Eva Maroto López; Shane Fitch; Lourdes Juarros; Marta Sánchez Cortés; Juan Luis Rodríguez Hermosa; Myriam Calle Rubio; María Teresa Hernández Criado; Marta López; Santiago Angulo-Díaz-Parreño; Aitor Martín-Pintado-Zugasti; Jordi Vilaró
Journal:  JMIR Mhealth Uhealth       Date:  2020-07-31       Impact factor: 4.773

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.